Drug quantification in single 3D organoids reveals correlation to reported in vivo brain uptake and demonstrates translational relevance for prediction of blood-brain barrier permeability
This study validates a quantitative 3D human BBB organoid model using UPLC-MS/MS, demonstrating that its drug uptake ratios significantly correlate with in vivo brain-to-plasma ratios and outperform current in silico prediction tools for assessing blood-brain barrier permeability.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human brain is a fortress, protected by a highly selective border known as the blood-brain barrier. This barrier acts as a gatekeeper, allowing essential nutrients to pass through while blocking most substances, including many life-saving medicines, from entering the central nervous system. For researchers trying to treat brain diseases, this gate is both a necessary shield and a frustrating obstacle. To develop effective drugs, scientists must first understand how well a potential medicine can cross this barrier. Traditionally, this has been done using animal tests or simple cell layers grown in flat dishes, but these methods often fail to accurately predict how a drug will behave in a human body. Animals differ from people in ways that matter for drug transport, and flat cell layers lack the complex three-dimensional structure found in real tissue. Consequently, promising drugs often fail in human trials because the earlier tests gave misleading results, while effective treatments for brain conditions remain out of reach.
A team of researchers at Heidelberg University has developed a new way to test drug permeability that bridges this gap. They created tiny, three-dimensional spheres of human cells, called organoids, that mimic the structure and function of the human blood-brain barrier. These organoids are built from three specific types of human cells: endothelial cells that form the blood vessel lining, pericytes that wrap around the vessels, and astrocytes that support the structure. When grown together, these cells self-assemble into a spherical cluster where the endothelial cells form a continuous outer layer, closely resembling the natural barrier found in the brain. The researchers then devised a method to measure exactly how much of a drug enters these tiny spheres. By using highly sensitive mass spectrometry, a technique that identifies and weighs molecules, they could quantify the amount of drug inside a single organoid after exposing it to a solution. This approach allowed them to calculate a ratio of drug concentration inside the sphere versus the surrounding liquid, providing a precise measure of how easily the drug crossed the barrier.
The study tested thirteen different drugs, including several used to treat brain tumors and other conditions. The researchers exposed the organoids to these drugs for varying amounts of time and measured the uptake. They found that the amount of drug entering the organoids correlated strongly with data from real human and animal studies regarding how much of those same drugs actually reach the brain in living bodies. Specifically, the ratio of drug inside the organoid to the drug outside matched the ratio of drug in the brain to the drug in the blood plasma observed in previous clinical and animal research. This correlation was not just a vague trend; the mathematical relationship was robust enough to suggest that this new model could reliably predict whether a drug would successfully enter the human brain. In contrast, when the researchers compared their results to predictions made by computer software tools designed to estimate brain penetration, those digital models showed no correlation with the real-world data. The computer models failed to capture the nuances that the living human cells in the organoids naturally demonstrated.
To ensure the organoids were functioning correctly, the team also tested the barrier's integrity. They used a small marker molecule that normally cannot pass through a tight barrier. When they treated the organoids with substances known to loosen the connections between cells, the marker was able to wash out more easily, confirming that the barrier's tightness could be altered and measured. They also checked the health of the cells, confirming that the organoids remained viable and that the cells maintained their specific shapes and connections over several days of culture. The optimal time to perform these tests was found to be three days after the cells were first mixed, a point where the barrier was fully formed and the cells were healthy. This timing allowed for consistent and reproducible results across many different experiments.
The significance of this work lies in its ability to provide a human-relevant test system that is both accessible and quantitative. Unlike previous models that relied on fluorescence or imaging, which can be limited by the size of the molecules they can detect, this method uses mass spectrometry to measure the actual chemical amount of drug inside the organoid. This allows for the detection of very small amounts of medication, making it possible to study drugs that do not easily cross the barrier. The researchers demonstrated that this system is a "New Approach Methodology," a term used for testing methods that reduce or replace the need for animal testing. By showing that their human cell model predicts real-world outcomes better than current computer simulations, the study offers a powerful tool for drug developers. It suggests that in the future, scientists could screen potential medicines on these human organoids to quickly identify which ones are likely to reach the brain and which will be blocked, streamlining the path to new treatments for brain disorders without relying on animal models or inaccurate computer guesses.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.